|
|
 | | | |
- close
- close
- close
- close
Cell Therapeutics (CTIC) |
QUOTE AND NEWS
StreetInsider.com
May 11
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CellTherapeutics+%28CTIC%29+Gets+Conditional+EC+Marketing+Authorization+for+Pixuvri/7428843.html for the full story.
Benzinga
May 10
Comment
Cell Therapeutics, Inc (Nasdaq: CTIC) today announced that it has received conditional marketing authorization from the European Commission for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or...
Marketwire
May 4
Comment
NEW YORK, NY -- (Marketwire) -- 05/04/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will
Value Investing
May 1
Comment
Stock symbols are the cornerstone of the stock market and a pure source of identity for companies. Billions of investment dollars change hands every day based on those little letters. Among traders of smaller-cap stocks, the companies are often...
TheStreet.com
Apr 19
Comment
SEATTLE (TheStreet) --
Cell Therapeutics CEO Jim Bianco threw another chainsaw into his reckless juggling act Thursday. Investors should avert their eyes, unless they enjoy the sight of inevitable severed limbs.
In Bianco latest act of...
FierceBiotech
Apr 19
Comment
Less than three months after announcing a puzzling about-face on its long and troubled quest for an approval of pixantrone, Cell Therapeutics ($CTIC) has stepped back up with a deal to buy S*BIO's pacritinib, an oral JAK2 inhibitor now in a...
Benzinga
Apr 19
Comment
Cell Therapeutics, Inc. (Nasdaq: CTIC) and S*BIO Pte Ltd announced yesterday that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2...
Marketwire
Mar 22
Comment
NEW YORK, NY -- (Marketwire) -- 03/22/12 -- In recent years, smaller biotechnology companies have received less funding from venture capitalists than in years past. According to the Biotechnology Industry Organization (BIO), roughly 61 percent of
Marketwire
Jan 31
Comment
NEW YORK, NY -- (Marketwire) -- 01/31/12 -- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
